Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| H-16038786 | Other Identifier | Committees on Health Research Ethics | |
| AHH-2016-067 (I-suite 04931) | Other Identifier | Danish Data Protection Agency |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Clinical Research Centre | UNKNOWN |
| Lundbeck Foundation | OTHER |
| Region Hovedstadens Apotek | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
In this study, the investigators will investigate and characterize acute medical patients in order to optimize patient courses in the acute care departments, especially with regard to polypharmacy and undernourishment. In addition, the investigators will investigate underlying immunological mechanisms of chronic inflammation and biological aging in this population to improve the current knowledge and possibilities for preventing chronic diseases and acute hospitalization.
Malnutrition:
Malnutrition among elderly is associated with frailty, including loss of weight, muscle mass, function and quality of life and also with an increased number of hospital admissions. In this study, the investigators aim to describe the development of and the risk factors for malnutrition from admission to 4 weeks after discharge, in addition the investigators wish to characterize the inflammatory state of the malnourished patients.
Inappropriate polypharmacy:
The broad variation among elderly in health, number of chronic diseases, organ function, biological age and function makes the prescription of drugs to this population a very complex task with a high risk of inappropriate medication. 5-30% of all non-elective admissions are caused by inappropriate medications, and many of these are preventable. Therefore, the investigators aim to investigate the feasibility of a pharmacist-geriatrician medication review in the acute care department and the effect on the Medication Appropriateness Index score (MAI-score) .
Chronic inflammation and biological aging:
Chronic inflammation and biological aging promote the development of age-related chronic diseases. There is a large variation in the rate of aging between individuals, in particular among the elderly. This means that the chronological age of a person often does not reflect its true state of aging, the biological age. This challenges the ability to provide appropriate care and to predict responses to treatment and interventions in elderly patients. The underlying causes and mechanisms of biological aging and chronic inflammation are not well understood. There are currently no validated methods for measuring biological age and no measures of chronic inflammation which can be used in an acute setting. Here, the investigators aim to test a novel model for chronic inflammation and investigate the role of the NLRP3 inflammasome, NFkB (nuclear factor kappa light chain enhancer of activated B cells) and miRNAs in biological aging and chronic inflammation.
The study is prospective with 3 groups of study participants: one group is included in the Acute Medical Department and two healthy control groups (one young and one older). The follow-up comprises two predefined examinations and any readmissions at our hospital. Furthermore, participants are followed in the national registries.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| FAM group (n=98) | ≥65 years. Acutely admitted medical patients. Included consecutively at admission to the Acute Medical Department at Amager and Hvidovre Hospital and Rigshospitalet - Glostrup. Follow-up at 4 weeks and 56 weeks after discharge and at any readmissions in the study period. Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality. If a patient uses ≥5 prescribed drugs before hospitalization, a medication review will be performed by a clinical pharmacist and a geriatrician. Sample size calculations were performed for each primary outcome, and the final sample size was based on the calculation for the eating validation scheme which resulted in the largest sample size. | ||
| Control group 1 (n=54) | ≥65 years. No hospital admissions within the past two years. Matched individually with patients in the FAM group by age, sex, and municipality. Examined at inclusion and 52 weeks after inclusion. Participants are interviewed on physical, mental and nutritional status, tested for functional and cognitive status, and have anthropometry, biochemistry, blood pressure, and immune activity measured. Participants are followed in national registries for information on diagnoses, hospital admissions, health care services used, and mortality. | ||
| Control group 2 (n=60) | 20-35 years No admissions due to chronic or critical illness within the past 5 years (except admissions related to child birth, abortion, appendicitis, poisoning, traumas, concussion etc.) Examined at inclusion and 4 weeks after inclusion. The examination includes a questionnaire about life style, a physical examination, and blood samples. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Eating validation scheme score | Development in nutritional status and risk factors of malnutrition within the FAM group. | From inclusion to 4 weeks after discharge |
| MAI score (Medication Appropriateness Index) | Difference in summed MAI-score per patient. MAI score between inclusion and first follow-up visit (FAM group) | From inclusion to 4 weeks after discharge |
| NF-kB (Nuclear Factor Kappa light chain enhancer og activated B cells) activity | The development in NF-kB activity between the groups will be investigated. The association of NF-kB activity with biological ageing-measured by chronic inflammation, and loss of function and cognition-will also be investigated. | From inclusion to 56 weeks after discharge |
| Chronic inflammation | Stability and discriminative ability of new model for chronic inflammation (Control group 2) | From inclusion to 4 weeks after inclusion |
| NLRP3 activity | Difference in NLRP3 inflammasome activity between groups. | From inclusion to 56 weeks after discharge |
| Measure | Description | Time Frame |
|---|---|---|
| Bodyweight (kg) | Development in bodyweight | From inclusion to 4 and 56 weeks after discharge |
| Quality of life | EQ-5D-5L(EuroQol-5Dimentions-5Llevels), mini geriatric depression score |
| Measure | Description | Time Frame |
|---|---|---|
| Sit-to-stand test | Development in physical performance | From inclusion to 56 weeks after discharge |
| Cognitive functional ability | Orientation memory concentration, mini mental state examination, Hopkins verbal learning test, trail making test, digit symbol substitution test |
FAM group:
Inclusion Criteria:
Exclusion Criteria:
Control group 1:
Inclusion Criteria:
Exclusion Criteria:
Control group 2:
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Three study groups; the FAM group, control group 1 and control group 2
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Ove Andersen, MD, PhD | Hvidovre University Hospital | Study Chair |
| Morten B. Houlind, MSc | Hvidovre University Hospital | Principal Investigator |
| Juliette Tavenier, MSc | Hvidovre University Hospital | Principal Investigator |
| Line JH Rasmussen, MSc | Hvidovre University Hospital | Principal Investigator |
| Aino L Andersen, MSc | Hvidovre University Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Amager & Hvidovre Hospital | Hvidovre | Capital Region | 2650 | Denmark |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36136804 | Derived | Bornaes O, Andersen AL, Houlind MB, Kallemose T, Tavenier J, Aharaz A, Nielsen RL, Jorgensen LM, Beck AM, Andersen O, Petersen J, Pedersen MM. Mild Cognitive Impairment Is Associated with Poorer Nutritional Status on Hospital Admission and after Discharge in Acutely Hospitalized Older Patients. Geriatrics (Basel). 2022 Sep 10;7(5):95. doi: 10.3390/geriatrics7050095. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D044342 | Malnutrition |
| D007249 | Inflammation |
| D004630 | Emergencies |
| ID | Term |
|---|---|
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
Not provided
Not provided
Not provided
Whole blood, plasma, serum, buffy coat.
| From inclusion to 56 weeks after discharge |
| Medication under-prescribing | Assessment of underutilization Index (AOU) | From inclusion to 4 weeks after discharge |
| Inflammation in malnourished patients | Characterize the level of inflammation in malnourished patients | 4 weeks after discharge |
| Functional recovery score | Assessing activities of daily living to characterize development in physical performance | From inclusion to 56 weeks after discharge |
| Cystatin C | From inclusion to 56 weeks after discharge |
| Cytokine concentrations | The concentration of cytokines at baseline and in response to stimulation will be measured | From inclusion to 56 weeks after discharge |
| Cytometry | Characterization of immune cell subsets | From inclusion to 56 weeks after discharge |
| miRNA | Levels of miRNA will be measured, and their association with NF-kB activity and biological ageing will be investigated. | From inclusion to 56 weeks after discharge |
| NF-kB activation | The activation of NF-kB in response to stimulation. | From inclusion to 56 weeks after discharge |
| C-reactive protein (inflammation) | Difference in inflammation between groups | From inclusion to 56 weeks after discharge |
| Soluble urokinase plasminogen activator receptor (suPAR) (ng/ml) | The plasma level of suPAR is a measure of inflammation and can be used to assess the difference in inflammation between groups | From inclusion to 56 weeks after discharge |
| Frequency of physicians' acceptance of suggested changes in medications | At inclusion and at 4 weeks after discharge in the FAM group |
| From inclusion to 56 weeks after discharge |
| Waist circumference (cm) | From inclusion to 56 weeks after discharge |
| Handgrip strength (kg) of dominant hand | Development in physical performance | From inclusion to 56 weeks after discharge |
| Habitual 4 m gait speed (m/s) | Development in physical performance | From inclusion to 56 weeks after discharge |
| Plasma and serum concentrations of admission blood samples | Routinely analyzed physiological biomarkers measured in plasma and serum | From inclusion to 56 weeks after discharge |
| Blood concentration of cholesterol and triglycerides | From inclusion to 56 weeks after discharge |
| Blood concentration of metabolic markers | Measurement of insulin, blood glucose, and HbA1c | From inclusion to 56 weeks after discharge |
| Plasma concentration of active drug substances | From inclusion to 56 weeks after discharge |
| CMV-IgG (Cytomegalovirus-immunoglobulin G) | Cytomegalovirus IgG titer | From inclusion to 56 weeks after discharge |
| D020969 | Disease Attributes |